Skip to content

CCTA and Dynamic CT Perfusion for the Diagnosis of Myocardial Ischemia in Patients With Coronary Stents

A Head-to-Head Prospective Comparison of Diagnostic Accuracy of CCTA and Dynamic CT Perfusion in Patients With Prior PCI for the Diagnosis of Myocardial Ischemia as Defined by Invasive Flow and Pressure Indices - PACIFIC-III

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04742933
Acronym
PACIFIC-III
Enrollment
140
Registered
2021-02-08
Start date
2021-10-25
Completion date
2024-04-01
Last updated
2021-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Computed tomography angiography, Computed tomography Perfusion, FFR, Prior revascularization

Brief summary

A single centre prospective trial in which patients with a prior PCI for stable CAD who are referred for invasive angiography will undergo state-of-the art CCTA and dynamic CT perfusion. Subsequently invasive FFR and iFR measurements will be routinely performed in each coronary vessel.

Detailed description

Rationale: Recent development in computed tomography (CT) hardware have fulfilled the prerequisites for clinical CT myocardial perfusion imaging (CTP). Cardiac CT, has by means of coronary computed tomography angiography (CCTA) and novel techniques such as CTP the unique ability to provide information on both the anatomical and functional severity of coronary artery disease (CAD). However, diagnostic performance of these novel techniques when referenced by the clinical diagnostic standard, invasive fractional flow reserve (FFR) measurements, has scarcely been investigated in patients with a prior PCI. Objective: To determine the diagnostic performance of CCTA and dynamic CTP for the diagnosis of myocardial ischemia using invasive coronary indices as the reference standard. Study design: The study is a single-center prospective comparative trial in which all patients will undergo CCTA and dynamic CTP before invasive coronary angiography (ICA) in conjunction with invasive flow/pressure measurements. Study population: Patients referred for a diagnostic ICA with a prior of PCI for stable CAD will be evaluated for inclusion in the study. Main study parameters/endpoints: Hemodynamic significant CAD as defined by an FFR ≤0.80 / iFR \< 0.90. Sensitivity, specificity, negative predictive value, positive predictive value and accuracy will be assessed for CCTA and dynamic CTP. In addition, this study will assess the prognostic value of CCTA and dynamic CTP in patients with a prior cardiac revascularization. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: A two day protocol will be completed after referral ensuring the diagnostic work-up of patients is not delayed. On day 1 patients will undergo CCTA and CTP. Then, on day 2, irrespective of CT results, patients will undergo ICA with invasive pressure measurements. The risks of CT are considered to be low. Patients are referred for a clinically indicated ICA and as such risks of the ICA are not deemed study-related. Future patients might benefit from the present study as combined anatomical information (CCTA) and functional information (dynamic CTP) might lead to a more judicious referral for ICA which leads to a reduction of exposure to invasive procedures such as ICA in combination with invasive pressure measurements.

Interventions

OTHERThere is no intervention in this observational trial

There is no intervention in this observational trial

Sponsors

Amsterdam UMC, location VUmc
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* History of PCI for stable CAD * Referred for a diagnostic ICA. * Age above 30 years.

Exclusion criteria

* History of severe COPD or chronic asthma * Pregnancy * Renal failure (eGFR \<30 mL/min) * Use of sildenafil (Viagra) or dipyramidol (Persantin) that cannot be terminated * Contra-indications for β-blockers * Allergic reaction to iodized contrast * Concurrent or prior (within last 30 days) participation in other research studies using investigational drugs * Claustrophobia * Significant co-morbidities * Atrial fibrillation, second or third degree atrioventricular block * Tachycardia * Acute myocardial infarction * History of CABG * Heart failure * Cardiomyopathies * Previous radiation exposure in the diagnostic work-up * Unable to give informed consent * Indispensable follow-up with (serial) CT scans for non-cardiac related condition

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and Specificity of Dynamic CT-perfusion and CCTA for CAD3 yearsFFR will be used as a reference standard, the primary endpoint is an abnormal FFR =\< 0.80. Diagnostic study using FFR as endpoun

Secondary

MeasureTime frameDescription
Major adverse cardiac events, cardiac death or repeat revascularization3 yearsThe secondary endpoint is to assess the prognostic value of CT in patients with a prior history of PCI

Countries

Netherlands

Contacts

Primary ContactRuurt A Jukema, MD
r.jukema@amsterdamumc.nl+312-4443262

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026